Novo-CFO: Here is the timeframe for Tresiba
The CFO of Novo Nordisk, Jesper Brandgaard, explains more about the ongoing dialogue with the FDA in regards to additional studies of diabetes drug Tresiba, and reveals what the US sales force will be used for until the time of approval.
by Stefan Singh Kailay
Best case scenario three years, worst case scenario five years. Those are the prospects for the US launch of long-acting insulin product Tresiba, Novo Nordisk CFO, Jesper Brandgaard, explains in connection with the publication of the company’s financial report for Q1 2013.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
